TY - JOUR
T1 - The first nationwide surveillance of antibacterial susceptibility patterns of pathogens isolated from skin and soft-tissue infections in dermatology departments in Japan
AU - Watanabe, Shinichi
AU - Ohnishi, Takamitsu
AU - Yuasa, Akira
AU - Kiyota, Hiroshi
AU - Iwata, Satoshi
AU - Kaku, Mitsuo
AU - Watanabe, Akira
AU - Sato, Junko
AU - Hanaki, Hideaki
AU - Manabe, Motomu
AU - Suzuki, Tamio
AU - Otsuka, Fujio
AU - Aihara, Michiko
AU - Iozumi, Ken
AU - Tamaki, Takeshi
AU - Funada, Yuichi
AU - Shinozaki, Mikio
AU - Kobayashi, Motoko
AU - Okuda, Masaru
AU - Kikyo, Go
AU - Kikuchi, Kumi
AU - Okada, Yoshitane
AU - Takeshima, Masanori
AU - Kaneko, Osamu
AU - Ogawa, Natsuki
AU - Ito, Rie
AU - Okuyama, Ryuhei
AU - Shimada, Shinji
AU - Shimizu, Tadamichi
AU - Hatta, Naohito
AU - Manabu, Maeda
AU - Tsutsui, Kiyohiro
AU - Tanaka, Toshihiro
AU - Miyachi, Yoshiki
AU - Asada, Hideo
AU - Furukawa, Fukumi
AU - Kurokawa, Ichiro
AU - Iwatsuki, Keiji
AU - Hide, Michihiro
AU - Muto, Masahiko
AU - Yamamoto, Osamu
AU - Niihara, Hiroyuki
AU - Takagaki, Kenji
AU - Kubota, Yasuo
AU - Sayama, Koji
AU - Sano, Shigetoshi
AU - Furue, Masutaka
AU - Kanekura, Takuro
N1 - Funding Information:
Hiroshi Kiyota received donations from Taisho Toyama Pharmaceutical Co., Ltd., Toyama Chemical Co., Ltd., Daiichi Sankyo Co., Ltd., Satoshi Iwata received speaker honoraria from Taisho Toyama Pharmaceutical Co., Ltd., Pfizer Japan Inc., and Meiji Seika Pharma Co., Ltd. Mitsuo Kaku received speaker honoraria from MSD K.K., Eiken Chemical Co., Ltd., Daiichi Sankyo Co., Ltd., Sumitomo Dainippon Pharma Co., Ltd., and Pfizer Japan Inc. Akira Watanabe received speaker honoraria from MSD K.K., Kobayashi Pharmaceutical Co., Ltd., Shionogi & Co., Ltd., Daiichi Sankyo Co., Ltd., Taisho Toyama Pharmaceutical Co., Ltd., Sumitomo Dainippon Pharma Co., Ltd., Mitsubishi Tanabe Pharma Co., Chugai Pharmaceutical Co., Ltd., Pfizer Japan Inc., and UCB Japan Co. Ltd.; donations from Astellas Pharma Inc., Daiichi Sankyo Co., Ltd., and Sumitomo Dainippon Pharma Co., Ltd.; payments for manuscript drafting and editing from Iyaku (Medicine and Drug) Journal Co., Ltd.; and grant support from Kyorin Pharmaceutical Co., Ltd., Shionogi & Co., Ltd., Daiichi Sankyo Co., Ltd., Taisho Toyama Pharmaceutical Co. Ltd., Taiho Pharmaceutical Co., Ltd., Toyama Chemical Co., Ltd., FUJIFILM Pharma Co., Ltd., and Meiji Seika Pharma Co., Ltd. Michiko Aihara received a donation from CALPIS Co., Ltd. Fukumi Furukawa received donations from COSE Corporation, Mruho Co., Ltd., and Torii Pharmaceutical Co., Ltd.; and grant support from JMEC Co., Ltd. Ichiro Kurokawa received speaker honoraria from Maruho Co., Ltd. and Glaxo Smithkline K.K. Shigetoshi Sano received donations from Mitsubishi Tanabe Pharma Corporation and Mruho Co., Ltd.
PY - 2017/8
Y1 - 2017/8
N2 - To investigate the trends of antimicrobial resistance in pathogens isolated from skin and soft-tissue infections (SSTI) at dermatology departments in Japan, a Japanese surveillance committee conducted the first nationwide survey in 2013. Three main organisms were collected from SSTI at 30 dermatology departments in medical centers and 10 dermatology clinics. A total of 860 strains – 579 of Staphylococcus aureus, 240 of coagulase-negative Staphylococci, and 41 of Streptococcus pyogenes – were collected and shipped to a central laboratory for antimicrobial susceptibility testing. The patient profiles were also studied. Among all 579 strains of S. aureus, 141 (24.4%) were methicillin-resistant (MRSA). Among 97 Staphylococcus epidermidis strains, 54 (55.7%) were methicillin-resistant (MRSE). MRSA and MRSE were more frequently isolated from inpatients than from outpatients. Furthermore, these methicillin-resistant strains were also isolated more frequently from patients with histories of taking antibiotics within 4 weeks and hospitalization within 1 year compared to those without. However, there were no significant differences in MIC values and susceptibility patterns of the MRSA strains between patients with a history of hospitalization within 1 year and those without. Therefore, most of the isolated MRSA cases at dermatology departments are not healthcare-acquired, but community-acquired MRSA. S. pyogenes strains were susceptible to most antibiotics except macrolides. The information in this study is not only important in terms of local public health but will also contribute to an understanding of epidemic clones of pathogens from SSTI.
AB - To investigate the trends of antimicrobial resistance in pathogens isolated from skin and soft-tissue infections (SSTI) at dermatology departments in Japan, a Japanese surveillance committee conducted the first nationwide survey in 2013. Three main organisms were collected from SSTI at 30 dermatology departments in medical centers and 10 dermatology clinics. A total of 860 strains – 579 of Staphylococcus aureus, 240 of coagulase-negative Staphylococci, and 41 of Streptococcus pyogenes – were collected and shipped to a central laboratory for antimicrobial susceptibility testing. The patient profiles were also studied. Among all 579 strains of S. aureus, 141 (24.4%) were methicillin-resistant (MRSA). Among 97 Staphylococcus epidermidis strains, 54 (55.7%) were methicillin-resistant (MRSE). MRSA and MRSE were more frequently isolated from inpatients than from outpatients. Furthermore, these methicillin-resistant strains were also isolated more frequently from patients with histories of taking antibiotics within 4 weeks and hospitalization within 1 year compared to those without. However, there were no significant differences in MIC values and susceptibility patterns of the MRSA strains between patients with a history of hospitalization within 1 year and those without. Therefore, most of the isolated MRSA cases at dermatology departments are not healthcare-acquired, but community-acquired MRSA. S. pyogenes strains were susceptible to most antibiotics except macrolides. The information in this study is not only important in terms of local public health but will also contribute to an understanding of epidemic clones of pathogens from SSTI.
KW - Community-acquired MRSA (CAMRSA)
KW - Methicillin-resistant S. aureus (MRSA)
KW - Skin and soft-tissue infection (SSTI)
KW - Surveillance
KW - Susceptibility
UR - http://www.scopus.com/inward/record.url?scp=85020883107&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85020883107&partnerID=8YFLogxK
U2 - 10.1016/j.jiac.2017.05.006
DO - 10.1016/j.jiac.2017.05.006
M3 - Article
C2 - 28645883
AN - SCOPUS:85020883107
VL - 23
SP - 503
EP - 511
JO - Journal of Infection and Chemotherapy
JF - Journal of Infection and Chemotherapy
SN - 1341-321X
IS - 8
ER -